To appraise the clinical and cost effectiveness of liposomal cytarabine and daunorubicin within its marketing authorisation for untreated, high risk, acute myeloid leukaemia.
 
Status In progress
Process STA pre-2018
ID number 1225

Provisional Schedule

Expected publication 09 January 2019

Project Team

Project lead Stephanie Callaghan

Email enquiries

Consultees

Companies sponsors Jazz Pharmaceuticals
Others Department for Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Leukaemia CARE
Professional groups Association of Cancer Physicians
  British Society for Haematologists
  Cancer Research UK
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists

Commentators

Comparator companies Accord Healthcare (cytarabine, doxorubicin hydrochloride, idarubicin hydrochloride, mitoxantrone) – (confidentiality agreement not signed, not participating)
  Celgene (azacitadine)
  Hospira UK (cytarabine) - (Confidentiality agreement not signed, not participating)
  Novartis Pharmaceuticals (midostaurin)
  Pfizer (cytarabine, doxorubicin hydrochloride, gemtuzumab ozogamicin, idarubicin hydrochloride)
  Zentiva (daunorubicin) - (confidentiality agreement not signed, not participating)
General commentators All Wales Therapeutic and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research

Timeline

Key events during the development of the guidance:

Date Update
21 February 2018 Invitation to participate
18 August 2017 - 18 September 2017 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
18 August 2017 In progress, In progress

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance